Northwest Biotherapeutics, Inc. (OTCMKTS:NWBO – Get Rating)'s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.74 and traded as low as $0.60. Northwest Biotherapeutics shares last traded at $0.60, with a volume of 902,059 shares.
Northwest Biotherapeutics Trading Down 4.6 %
The firm has a 50-day moving average of $0.67 and a 200 day moving average of $0.74. The stock has a market capitalization of $644.77 million, a price-to-earnings ratio of -5.96 and a beta of -0.03.
Northwest Biotherapeutics Company Profile
(Get Rating)
Northwest Biotherapeutics, Inc is a biotechnology company, which engages in the development of personalized immune therapies for cancer. It offers DCVax technology platform, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The company was founded by Alton L.
Featured Stories
- Get a free copy of the StockNews.com research report on Northwest Biotherapeutics (NWBO)
- Dave & Buster's Rebound Could Score for Investors
- Cal-Maine: Is it Time to Chase this Stock Higher?
- The Most Important Warren Buffett Stock for Investors: His Own
- Three Mid Caps Wall Street Sees Doubling Within 12 Months
- It's No Stretch: Lululemon Could Break Out of its Range
Receive News & Ratings for Northwest Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Northwest Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
在週三的交易中,西北生物治療公司的股價跌破了200日移動均線。該股的200日移動均線為0.74美元,最低交易價格為0.60美元。西北生物治療公司的股票最新報0.60美元,成交量為902,059股。
西北生物治療公司股價下跌4.6%
該公司的50日移動均線切入位在0.67美元,200日移動均線切入位在0.74美元。該股市值為6.4477億美元,本益比為-5.96倍,貝塔係數為-0.03。
西北生物治療公司簡介
(獲取評級)
西北生物治療公司是一家生物技術公司,致力於開發針對癌症的個性化免疫療法。它提供了DCVax技術平臺,該平臺使用激活的樹突狀細胞來動員患者自己的免疫系統來攻擊他們的癌症。該公司是由Alton L.
專題報道
- 免費獲取StockNews.com關於西北生物療法(NWBO)的研究報告
- Dave&Buster的反彈可能會為投資者帶來好處
- 加州緬因州:是時候追逐這只股票了嗎?
- 對投資者來說最重要的沃倫·巴菲特股票:他自己的股票
- 華爾街預計三隻中型股在12個月內翻一番
- 這是不可伸展的:lululemon可以突破它的範圍
接受《西北生物療法日報》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對西北生物治療公司和相關公司的最新新聞和分析師評級的每日簡要摘要。